Ignite Creation Date:
2025-12-24 @ 4:32 PM
Ignite Modification Date:
2026-03-03 @ 10:03 AM
Study NCT ID:
NCT03656666
Status:
UNKNOWN
Last Update Posted:
2023-03-29
First Post:
2018-08-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005831', 'term': 'Genital Diseases, Female'}], 'ancestors': [{'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C505730', 'term': 'apremilast'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Double-blinded, randomized, placebo-controlled trial'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 42}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2019-09-24', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-03', 'completionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-03-28', 'studyFirstSubmitDate': '2018-08-15', 'studyFirstSubmitQcDate': '2018-08-31', 'lastUpdatePostDateStruct': {'date': '2023-03-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-09-04', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-11-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Description of immune histochemical changes and expression of selected cytokines before and after apremilast therapy, assessed in vulvar or vaginal biopsies', 'timeFrame': '24 weeks', 'description': 'Asessment in biopsies at week 0 and 24'}, {'measure': 'Description of extragenital lichen planus at week 0, 16 and 24', 'timeFrame': '24 weeks', 'description': 'Extragenital lichen planes is described and compared at 0,16 and 24 weeks'}, {'measure': 'Evaluation of clinical photos', 'timeFrame': '24 weeks', 'description': 'Clinical photos of lichen planus lesions are taken by a medical photographer at week 0 and 24'}, {'measure': 'Adverse events', 'timeFrame': '24 weeks', 'description': 'Adverse events are registered at time point described in the protocol'}], 'primaryOutcomes': [{'measure': 'Mean GELP score at week 24 in apremilast-treated patients versus placebo-treated patients', 'timeFrame': '24 weeks', 'description': 'The GELP (Genital Erosive Lichen Planus) score is a scoring system for clinical assessment of genital erosive lichen planus (GELP) in women. Area of genital involvement, erythema, striae, number of erosions and pain are registered and scored 0-3 (0 is none) for each parameter. Vulval and vaginal involvement is assessed separately, resulting in a maximum GELP score of 30.'}], 'secondaryOutcomes': [{'measure': 'Mean GELP score improvement from week 0 to week 24 in all patients', 'timeFrame': '24 weeks', 'description': 'The GELP (Genital Erosive Lichen Planus) score is a scoring system for clinical assessment of genital erosive lichen planus (GELP) in women. Area of genital involvement, erythema, striae, number of erosions and pain are registered and scored 0-3 (0 is none) for each parameter. Vulval and vaginal involvement is assessed separately, resulting in a maximum GELP score of 30.'}, {'measure': 'Weekly use of topical steroid, collected from patient diary', 'timeFrame': '24 weeks', 'description': 'Frequency of application is recorded once a week in the patient diary as the number of days being used per week'}, {'measure': 'Weekly VAS pain score, collected from patient diary', 'timeFrame': '24 weeks', 'description': 'VAS is recorded once a week in the patient diary using a visual linear scale of 100mm ranging from 0 (no pain) to 10 (worst imaginable pain).'}, {'measure': 'Number of patients with GELP score improvement at week 16 and 24', 'timeFrame': '24 weeks', 'description': 'The GELP (Genital Erosive Lichen Planus) score is a scoring system for clinical assessment of genital erosive lichen planus (GELP) in women. Area of genital involvement, erythema, striae, number of erosions and pain are registered and scored 0-3 (0 is none) for each parameter. Vulval and vaginal involvement is assessed separately, resulting in a maximum GELP score of 30.'}, {'measure': 'Separate GELP score assessments: Area of involvement (in cm²)', 'timeFrame': '24 weeks', 'description': 'Range 0-3 (none=0, \\<3 cm²=1, 3-6 cm²=2, \\>6 cm²=3). Recorded as part of the GELP score at time points specified in the protocol.'}, {'measure': 'Separate GELP score assessments: Intensity of erythema', 'timeFrame': '24 weeks', 'description': 'Range 0-3 (none=0, mild=1, moderate=2, strong=3). Recorded as part of the GELP score at time points specified in the protocol.'}, {'measure': 'Separate GELP score assessments: Number of erosions', 'timeFrame': '24 weeks', 'description': 'Range 0-3 (none=0, 1=1, 2-3=2, \\>3=3). Recorded as part of the GELP score at time points specified in the protocol.'}, {'measure': 'Separate GELP score assessments: Striae', 'timeFrame': '24 weeks', 'description': 'Range 0-3 (none=0, minimal=1, moderate=2, extensive=3). Recorded as part of the GELP score at time points specified in the protocol.'}, {'measure': 'Separate GELP score assessments: Pressure-induced pain (VAS)', 'timeFrame': '24 weeks', 'description': 'Patient-reported pain is induced by pressuring the involved area with a cotton swab, using a visual linear scale of 100mm ranging from 0 (no pain) to 10 (worst imaginable pain). GELP score range 0-3 (no pain=0, VAS 1-3=1, VAS 4-6=2,VAS 7-10=3). Recorded as part of the GELP score at time points specified in the protocol.'}, {'measure': 'Physician Global Assessment (PGA)', 'timeFrame': '24 weeks', 'description': '5-point disease severity scoring system, assessed by the clinician at time points specified in the protocol (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).'}, {'measure': 'Patient Global Assessment (PtGA)', 'timeFrame': '24 weeks', 'description': '5-point disease severity scoring system, assessed by the patient at time points specified in the protocol (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe).'}, {'measure': 'DLQI score', 'timeFrame': '24 weeks', 'description': 'The Dermatology Life Quality Index (DLQI) is a 10-question validated questionnaire. Each question is scored 0-3, with a maximum score of 30. The higher the score, the more quality of life is impaired. The time points for DLQI score are specified in the protocol.'}, {'measure': 'GHQ-28 score', 'timeFrame': '24 weeks', 'description': 'GHQ-28 is a 28-item version of the General Health Questionnaire (GHQ) subdivided into somatic symptoms, anxiety/insomnia, social dysfunction and severe depression. Each question is scored 0-1. The higher the score, the more severe the condition.The time points for GHQ-28 score are specified in the protocol.'}, {'measure': 'Sexual function assessments', 'timeFrame': '24 weeks', 'description': 'The Female Sexual Distress Scale - Revised (FSDS-R) is a 13-item questionnaire used for sexual function assessment. Each question is scored 0-4. The total score range is 0-52, with higher scores indicating more sexually related distress.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['apremilast', 'genital erosive lichen planus'], 'conditions': ['Lichen Planus of Vulva', 'Female Genital Disease']}, 'descriptionModule': {'briefSummary': 'Genital erosive lichen planus (GELP) is a chronic inflammatory disease causing painful genital sores and scarring in women. Treatment options are limited and often unsatisfactory. This trial will study the effects of treatment with apremilast and quality of life and sexual function in women with GELP.', 'detailedDescription': 'Genital erosive lichen planus (GELP) is a chronic, inflammatory and scarring genital disease. The disease may have a significant impact on daily living, quality of life and sexual function. There is a considerable lack of high-quality evidence on treatment options for GELP and few effective therapeutic facilities available in current clinical practice.\n\nThe aims of this study are to investigate clinical and immunohistochemical effects of a new oral anti-inflammatory treatment, apremilast, for women with moderate-to-severe GELP in a double-blinded, randomized, placebo-controlled trial (RCT). Apremilast is an inhibitor of phosphodiesterase 4 (PDE4) with documented effect in several inflammatory skin diseases, but it has not yet been studied in patients with GELP. The drug dose and study design have been chosen based on relevant experience from other studies on apremilast, and is equivalent to the dose used for approved indications (chronic plaque psoriasis and psoriatic arthritis).\n\nThe main objective of this trial is to assess the efficacy of apremilast in the treatment of GELP in women.\n\nSecondary objectives include\n\n* Description of immunohistochemical changes in lichen planus lesions\n* Assessment of safety of apremilast in the treatment of GELP\n* Assessment of quality of life and sexual function'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Moderate to severe GELP at inclusion with the diagnosis based on characteristic clinical and/or histological features. Minimum GELP score 5/30 in vagina and/or vulva (scored separately), of which erythema and pain ≥1 are mandatory\n* Informed consent from the patient to the protocol and clinical procedures.\n\nExclusion Criteria:\n\n* Patients receiving other systemic immune modulating therapy\n* Concomitant use of strong CYP3A4 enzyme inducers\n* Inadequate birth control, pregnancy and/or breast-feeding\n* Depression and suicidal ideation\n* Patients with severe renal impairment\n* Patients with active tuberculosis, serious infections or cancer\n* Unexplained and clinically significant weight loss in underweight patients\n* Hypersensitivity to the active substance(s) or to any of the excipients\n* Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption\n* Participating in another trial that might affect the current study or there should be minimum 90 days between participation in another intervention trial'}, 'identificationModule': {'nctId': 'NCT03656666', 'briefTitle': 'The AP-GELP Study: A Clinical Trial on the Effects of Apremilast in Female Genital Erosive Lichen Planus', 'organization': {'class': 'OTHER', 'fullName': 'Oslo University Hospital'}, 'officialTitle': 'The AP-GELP Study: A Randomized, Placebo-Controlled Clinical Trial on the Effects of Phosphodiesterase 4-Inhibitor Apremilast in Female Genital Erosive Lichen Planus', 'orgStudyIdInfo': {'id': 'AP-GELP'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'ACTIVE_COMPARATOR', 'label': 'Apremilast', 'description': 'Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.\n\nInitial titration:\n\nDay 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily.', 'interventionNames': ['Drug: Apremilast']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo + Apremilast', 'description': 'Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'Apremilast', 'type': 'DRUG', 'otherNames': ['Otezla'], 'description': 'Apremilast oral tablets', 'armGroupLabels': ['Apremilast']}, {'name': 'Placebo', 'type': 'DRUG', 'otherNames': ['Placebo (for apremilast)'], 'description': 'Placebo oral tablets', 'armGroupLabels': ['Placebo + Apremilast']}]}, 'contactsLocationsModule': {'locations': [{'zip': '0424', 'city': 'Oslo', 'country': 'Norway', 'facility': 'Oslo University Hospital HF', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}], 'overallOfficials': [{'name': 'Anne Lise Helgesen, MD PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Oslo University Hospital HF'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Oslo University Hospital', 'class': 'OTHER'}, 'collaborators': [{'name': 'Celgene Corporation', 'class': 'INDUSTRY'}, {'name': 'Amgen', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Anne Lise Helgesen', 'investigatorAffiliation': 'Oslo University Hospital'}}}}